Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 2/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27955484 | 0.78 | FFAR3 (0.42) | FFAR3TSHRCYP2C19 | |
| SCHEMBL9372565 | 0.73 | CYP2C19 (0.40) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL28407071 | 0.71 | CYP2C19 (0.39) | FFAR3TSHRCYP2C19 | |
| SCHEMBL23245204 | 0.70 | CYP2C19 (0.42) | FFAR3TSHRCYP2C19 | |
| SCHEMBL11208917 | 0.70 | CYP2C19 (0.42) | FFAR3TSHRCYP2C19 | |
| SCHEMBL15114681 | 0.69 | FFAR3 (0.48) | FFAR3NFKB1CYP2C19 | |
| SCHEMBL31394600 | 0.68 | FFAR3 (0.36) | FFAR3 | |
| SCHEMBL10276856 | 0.68 | CYP2C19 (0.46) | FFAR3TSHRCYP2C19 | |
| SCHEMBL3831087 | 0.68 | CYP2C19 (0.46) | FFAR3TSHRCYP2C19 | |
| SCHEMBL358029 | 0.68 | CYP2C19 (0.46) | FFAR3TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174672-A1 | FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS | S1PR1, S1PR2, S1PR3 | FFAR3 127/4885TSHR 1001/4885NFKB1 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.